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Evolution of the “fourth stage” of
epidemiologic transition in people aged
80 years and over: population-based cohort
study using electronic health records
Nisha C. Hazra1* and Martin Gulliford1,2
Abstract
Background: In the “fourth stage” of epidemiological transition, the distribution of non-communicable diseases is
expected to shift to more advanced ages, but age-specific changes beyond 80 years of age have not been reported.
Methods: This study aimed to evaluate demographic and health transitions in a population aged 80 years and over in
the United Kingdom from 1990 to 2014, using primary care electronic health records. Epidemiological analysis of
chronic morbidities and age-related impairments included a cohort of 299,495 participants, with stratified sampling by
five-year age group up to 100 years and over. Cause-specific proportional hazards models were used to estimate hazard
ratios for incidence rates over time.
Results: Between 1990 and 2014, nonagenarians and centenarians increased as a proportion of the over-80 population,
as did the male-to-female ratio among individuals aged 80 to 95 years. A lower risk of coronary heart disease (HR 0.54,
95% confidence interval [CI]: 0.50–0.58), stroke (0.83, 0.76–0.90) and chronic obstructive pulmonary disease (0.59, 0.54–0.
64) was observed among 80–84 year-olds in 2010–2014 compared to 1995–1999. By contrast, the risk of type II diabetes
(2.18, 1.96–2.42), cancer (1.52, 1.43–1.61), dementia (2.94, 2.70–3.21), cognitive impairment (5.57, 5.01–6.20), and
musculoskeletal pain (1.26, 1.21–1.32) was greater in 2010–2014 compared to 1995–1999.
Conclusions: Redistribution of the over-80 population to older ages, and declining age-specific incidence of
cardiovascular and respiratory diseases in over-80s, are consistent with the “fourth stage” of epidemiologic transition,
but increases in diabetes, cancer, and age-related impairment show new emerging epidemiological patterns in the
senior elderly.
Keywords: Epidemiological transition, Incidence, Very old, Senior elderly, Chronic disease, Morbidity, Epidemiology,
Primary care, UK
Background
The epidemiologic transition theory, proposed by Omran
in 1971 [1], was developed from the demographic transition
model [2] adding a more detailed consideration to causes
of mortality [3]. The theory accounts for changes in age-
and cause-specific mortality associated with development,
generally characterized by a decline in mortality from infec-
tious diseases and reproductive conditions, accompanied by
the emergence of chronic non-communicable diseases as
the most important causes of death [4]. Empirical studies
from the United Kingdom [5–7] and other countries [3, 8]
have supported the general outline of Omran’s theory, but
have also identified some shortcomings. In middle- and
low-income countries, the emergence of HIV-related mor-
tality and the impact of war and civil conflict show that
changes in mortality are not always consistent with the dir-
ection of theory [9]. In high-income countries, the epidemi-
ologic transition theory as originally proposed did not
account for the decline in non-communicable diseases that
began to be observed soon after its publication. Olshansky
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and Ault [10] proposed a “fourth stage” of epidemiologic
transition, “The Age of Delayed Degenerative Diseases,” in
which declining age-specific mortality results in a gradual
shift of non-communicable burden to older ages, with
underlying causes of death showing little change overall.
However, Modig et al. reported that case fatality following
myocardial infarction (MI) has fallen steadily in Sweden in
every year of age up to 100 since the mid-1990s [11]. This
“fourth stage” of transition is associated with population
aging and has assumed great importance as the senior eld-
erly population, aged 80 years and older, has increased.
The epidemiologic transition theory is primarily con-
cerned with changing patterns in mortality [12]. Morbid-
ity, the incidence of diseases and health conditions, have
generally been omitted from direct consideration, despite
disease incidence being an important driving factor re-
sponsible for key outcomes described in the theory. There
is a gap in our understanding with respect to age-specific
changes in morbidity above the age of 80 years, with most
studies analyzing all elderly together as a single group.
The World Health Organization’s recent 2015 report on
Ageing and Health [13] highlights the importance of char-
acterizing aging processes as a crucial element of the
health agenda. The present study therefore analyzes elec-
tronic health records (EHRs) from a large primary care
database in the UK to describe demographic and epi-
demiological changes in a population of senior elderly
aged 80 years and older between 1990 and 2014. EHRs
have been identified as a valuable resource for research
into the population effect of changing demography on the
epidemiology of chronic illnesses [14]. Analyses specific-
ally aimed to describe changes in the age and sex distribu-
tion of the senior elderly population and to relate these to
changes in the incidence of chronic diseases and age-
related impairments, as drivers of changes in mortality.
The results are discussed in terms of the insight these pro-
vide into the progress of the “fourth stage” of epidemio-
logic transition in the UK.
Methods
Data source
Data were obtained from the Clinical Practice Research
Datalink (CPRD), a nationally representative database of
EHRs in the UK containing anonymized patient records
for approximately 7% of the UK population [15–17]. The
CPRD population has been shown to be representative of
the UK population with respect to age, gender, and geo-
graphical distribution [15, 18]. Data collection occurs daily
as a part of normal clinical care of patients registered with
participating practices [15]. The frequency of data collec-
tion is determined by patient need and patients are in-
cluded in the dataset from first contact until last contact
with the practice. This population-based cohort study was
approved through a protocol submitted to the Medicines
and Healthcare Products Regulatory Agency (MHRA) In-
dependent Scientific Advisory Committee (ISAC) for
CPRD studies (Protocol No. 15_047).
Demographic data and analysis
Demographic data were obtained from the March 2015
release of CPRD, including a complete listing of the start
and end dates of CPRD records, year of birth, and date
of death for all participants contributing data to CPRD.
The proportion of senior elderly in the total CPRD
population was determined based on individuals reach-
ing the age of 80 years or greater, by sex and five-year
period from 1990 to 2014, using mid-year counts. For
each five-year period, the proportion of senior elderly in
each five-year age-group, per 1,000 population, was esti-
mated including changes over time in the past two de-
cades and 95% confidence intervals calculated using the
Poisson distribution. Mid-year counts were calculated by
including individuals reaching the age of 80 years or
greater, with an active record on 30 June during the year
of interest. These were aggregated for individuals
80 years or over as the numerator, with mid-year counts
for all ages as denominator. Sex ratios, as the number of
men per 100 women, were estimated in each year for the
populations aged ≥80, ≥85, ≥90, ≥95, and ≥100 years. Mov-
ing averages were used for the age groups ≥95 and
≥100 years in order to smooth the trend line due to smaller
numbers. The age at death for individuals who died at the
age of 80 years or over was plotted by year of death.
Epidemiological data and analysis
For epidemiological analysis, a stratified random sample
was selected from the list of all patients registered at
CPRD general practices. The list of eligible participants
was first divided into those who had reached their 80th,
85th, 90th, 95th, and 100th birthdays while registered
with CPRD during the study period, 1st January 1990 to
31st December 2014. A random sample of up to a max-
imum of 50,000 men and 50,000 women was taken from
each stratum, resulting in 299,495 participants (168,782
females and 130,713 males) aged 80 years and over, in-
cluding 10,560 reaching 100 years or older.
Case definitions were developed for the outcomes of cor-
onary heart disease (CHD) [19], stroke [20], type II diabetes
mellitus (DM) [21], chronic obstructive pulmonary disease
(COPD), and cancer (malignant neoplasms). Age-related
impairments included dementia, cognitive and memory im-
pairment, musculoskeletal (MSK) pain, falls, factures, and
hearing impairment and visual impairment, as reported
previously [22]. We estimated incidence rates for the onset
of a new chronic condition or age-related impairment
(Additional file 1), and used a cause-specific propor-
tional hazards models to estimate hazard ratios [23, 24],
reflecting changes over time. We acknowledge the
Hazra and Gulliford Population Health Metrics  (2017) 15:18 Page 2 of 10
potential importance of competing risks for future studies
that might report on cumulative incidence of specific out-
comes. Models were estimated separately for each five-
year age-group including: 80–84 years, 85–89 years, 90–
94 years, 95–99 years, and 100+ years. We contrasted two
decades, divided into four five-year periods: 1995–1999,
2000–2004, 2005–2009, and 2010–2014. The years 1990–
1994 were omitted in order to focus analysis on the most
recent two decades. Multiple records were analyzed, based
on successive age-groups and time periods for each
participant. Hazard ratios (HRs) were adjusted for time
and sex, and estimated in each age-group comparing each
period to 1995–1999 as the reference period. The propor-
tional hazards assumption was evaluated through estima-
tion of Schoenfeld residuals. Analyses were conducted
using Stata version 14.0.
Results
The total CPRD registered population increased, follow-
ing the recruitment of family practices, from 1.16 million
in 1990–1994 to 4.77 million in 2005–2009 before de-
clining to 4.45 million in 2010–2014 (Table 1). The
number of individuals aged 80 years and older in CPRD
increased from 53,008 (36,533 women, 16,475 men) in
1990–1994 to 226,479 (141,359 women, 85,119 men) in
2010–2014. The proportion of the total population aged
≥80 years increased from 45.7 per 1,000 (95% confidence
interval [CI]: 45.3–46.1) in 1990–1994 to 50.9 per 1,000
(95% CI: 50.7–51.1) in 2010–2014; for women the in-
crease was from 61.0 per 1,000 (95% CI: 61.2–62.5) to
63.0 per 1000 (95% CI: 62.7–63.3), and in men the in-
crease was greater, from 28.9 per 1,000 (95% CI: 28.5–
29.4) to 38.6 per 1,000 (95% CI: 38.4–38.9). While the
proportion of men ≥80 years showed a consistent in-
crease in successive periods, the proportion of women
≥80 years declined by 0.5 per 1,000 from 2005–2009 to
2010–2014 (Table 1).
As expected, each successive five-year age-group over
80 years represented a decreasing proportion of the total
senior elderly population (Table 2). However, the oldest
age groups generally showed the largest relative increases
over time. The proportion of women aged 80–84 years de-
creased from 36.5% of the total over-80 population to
29.0% between 1990–1994 and 2010–2014. Men aged 90–
94 years and women aged 100 years and older were the
fastest growing groups, as proportions of all over-80s. Sex
difference in the numbers of senior elderly has declined
over the past two decades (Fig. 1); the ratio of men per
100 women aged 80 years and older increased over the
study period from 44.5 men per 100 women in 1990 to
62.7 men per 100 women in 2014. In the 85-and-over age-
group, the sex gap narrowed from 35.1 men per 100
women to 52.2 per 100, and in the 90-and-over age-group
from 28.1 to 40.9 men per 100 women. A lesser change
over time is observed for the group aged 95 years or
greater. Since 1990, mean age at death among the senior
elderly increased by two years; from 87 years to 89 years
in women, and from 85 to 87 years in men (Fig. 2).
Changes over time in the risk of new chronic condi-
tions are presented in Table 3, with the total number of
events (Additional file 1) and overall incidence rates by
age-group presented in Fig. 3. The relative hazard for CHD
declined over time; at 80–84 years, CHD incidence was
46% lower (HR 0.54, 95% CI: 0.50–0.58) in 2010–2014
compared to 1995–1999 (Table 3). This decline was con-
sistently observed in each age-group, with the exception of
centenarians presenting a higher relative hazard for CHD
in the most recent five-year period. This increased relative
hazard might suggest a cohort effect but the data were not
consistent, with a lower relative hazard being observed in
earlier years. This may be a result of smaller numbers in
this oldest age-group given the multiple comparisons being
undertaken. The relative hazard for stroke at 90–94 years
was 41% lower (HR 0.59, 95% CI: 0.54–0.65) in 2010–2014
compared to baseline. A decrease in stroke over time was
Table 1 Proportion of CPRD population aged 80 years or older by five-year period and sex
Period Total population 80+ years per thousand
total population
(95% CI)
Female population 80+ years per thousand
total population
(95% CI)
Male population 80+ years per thousand
total population
(95% CI)
80+
years
All ages
(millions)
80+
years
All ages
(millions)
80+
years
All ages
(millions)
1990-
1994
53,008 1.16 45.7 (45.3 to 46.1) 36,533 0.59 61.0 (61.2 to 62.5) 16,475 0.57 28.9 (28.5 to 29.4)
1995-
1999
96,266 2.06 46.7 (46.4 to 47.0) 65,649 1.04 62.9 (62.4 to 63.4) 30,617 1.02 30.1 (29.8 to 30.4)
2000-
2004
195,829 4.03 48.5 (48.3 to 48.8) 130,126 2.03 64.0 (63.7 to 64.4) 65,703 2.00 32.8 (32.6 to 33.1)
2005-
2009
235,745 4.77 49.4 (49.2 to 49.6) 152,266 2.40 63.5 (63.2 to 63.8) 83.479 2.37 35.2 (35.0 to 35.4)
2010-
2014
226,479 4.45 50.9 (50.7 to 51.1) 141,359 2.24 63.0 (62.7 to 63.3) 85,119 2.20 38.6 (38.4 to 38.9)
Figures are means of annual mid-year counts for each period, except where indicated
CI, confidence interval; CPRD, Clinical Practice Research Datalink
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observed in all five-year age-groups over 80 years. The
relative hazard for COPD was 76% lower (HR 0.24, 95%
CI: 0.18–0.30) in 2010–14 among those aged 95–99 years.
By contrast, relative hazards for cancer and diabetes in-
creased over the study period. In 2010–2014, cancer risk
was 38% higher for 90–94 year olds and 69% higher for
centenarians compared to 1995–1999. All age groups
showed a similar successive risk increase for cancer with
each five-year period. Diabetes risk increased by 118% for
80–84 year olds, and 451% for 85–89 year olds over the
study period, but there were no new reported cases of dia-
betes over the age of 90 years.
Incidence of age-related impairments has generally in-
creased over time (Table 4) across all age-groups. New
diagnoses of dementia increased by almost two-fold since
1995–1999 among individuals aged 80–84 years (HR 2.94,
95% CI: 2.70–3.21), while newly recorded cognitive im-
pairment and memory problems were 4–5 times higher in
2010–2014 compared to 1995–1999 among those aged
80–84 years (HR 5.57, 95% CI: 5.01–6.20), 90–94 years
Table 2 Proportion of the population aged 80 years and over by age-group and sex
80-84 years 85-89 90-94 95-99 100+ Total men &
women 80+
MEN
1990-1994 51,820 (19.6) 22,429 (8.5) 6,502 (2.5) 1,317 (0.50) 309 (0.12) 265,042
1995-1999 89,043 (18.5) 46,168 (9.6) 14,270 (3.0) 3,150 (0.65) 452 (0.09) 481,328
2000-2004 198,396 (20.3) 89,394 (9.1) 32,699 (3.3) 6,642 (0.68) 1,385 (0.14) 979,146
2005-2009 241,232 (20.5) 126,346 (10.7) 39,629 (3.4) 8,693 (0.74) 1,497 (0.13) 1,178,725
2010-2014 236,290 (20.9) 129,861 (11.5) 48,552 (4.3) 9,176 (0.81) 1,717 (0.15) 1,132,393
Change relative to 1990-1994 +6.7% +35.5% +74.8% +63.1 +30.1
WOMEN
1990-1994 96,683 (36.5) 56,824 (21.4) 22,761 (8.6) 5,313 (2.0) 1,084 (0.41) 265,042
1995-1999 159,566 (33.2) 107,675 (22.4) 46,473 (9.7) 12,545 (2.6) 1,986 (0.41) 481,328
2000-2004 328,522 (33.6) 193,143 (19.7) 97,149 (9.9) 26,792 (2.7) 5,024 (0.51) 979,146
2005-2009 364,524 (30.9) 248,815 (21.1) 107,778 (9.1) 33,685 (2.9) 6,526 (0.55) 1,178,725
2010-2014 328,498 (29.0) 225,332 (19.9) 115,227 (10.2) 31,016 (2.7) 6,724 (0.59) 1,132,393
Change relative to 1990-1994 -20.5% -7.2% +18.5% +36.6% +45.2%
Figures are sum of mid-year counts (% of total population aged 80 years and over)
Fig. 1 Sex ratios of the number of men per 100 women between 1990 and 2014
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(HR 6.30, 95% CI: 5.40–7.34) and 95–99 years (HR 6.62,
95% CI: 4.89–8.95). MSK pain, hearing impairment, falls,
and fractures increased by approximately 30–40% in 80–
84 year olds, with larger increases in older age-groups.
Risk of falls and fractures among centenarians increased
by 50% (HR 1.50, 95% CI: 1.12–2.02) and 57% (HR 1.57,
95% CI: 1.09–2.27), respectively. Figure 3 illustrates inci-
dence rates across the whole study period by age-group.
Incidence of the majority of impairments increased with
age, declining beyond 95 years and in centenarians. In
contrast, the majority of chronic conditions declined with
age, except for stroke which increased from 80 to 95 years,
and presented lower rates among centenarians.
Discussion
Our data illustrate that the population aged 80 years and
older is growing rapidly, with the most rapid growth, in
relative terms, being among men aged 90 to 94 years
and women aged 100 years or greater. The sex gap in
numbers of senior elderly is reducing while the mean
age at death is increasing. Our study also presents new
morbidity estimates for cause-specific hazards in the se-
nior elderly, which are among the first age-stratified
estimates reported for men and women aged 80 to
100 years or greater. These results offer support to the
proposed shift in mortality from non-communicable dis-
eases to advanced ages, consistent with the “fourth
stage” of epidemiologic transition or “The Age of De-
layed Degenerative Diseases.” However, this empirical
data also indicate that new and important epidemio-
logical patterns are emerging in the senior elderly. While
age-specific incidence for cardiovascular and respiratory
diseases is declining, rates of diabetes and cancer are in-
creasing substantially. In addition, a range of age-related
impairments are increasingly occurring and rising in im-
portance at the oldest ages, including dementia, cogni-
tive impairment, and falls. This is consistent with the
emergence of “frailty,” characterized by the accumulation
of functional deficits [25], as a key epidemiologic finding
in the latest stage of epidemiologic transition.
Comparison with existing literature
While the decline in cardiovascular diseases (CVDs) is
well-described, evidence for the extremes of age is
sparse, but some studies have suggested declining inci-
dence and mortality from CHD in adults aged more than
Fig. 2 Mean age at death for senior elderly by year of death. Legend: Grey, Women; Black, Men; Bars are 95% confidence intervals
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75 years [26, 27]. There is also evidence of a decline in
CVD risk in Sweden, including both MI and stroke, for
the period between 1994 to 2010 observed beyond
85 years, with the rate of improvement plateauing with
age [11]. This is consistent with our findings for CHD,
but not for stroke. Stroke incidence in the UK is re-
ported to have declined by 42% between 1999 and 2008
in individuals aged 80 years or greater [28]. We similarly
found declines in stroke incidence over time, but also re-
port these decreases among the senior elderly becoming
larger in magnitude with each increasing age-group up
to 100+ years; a 17% decline (HR 0.83, 95% CI: 0.76–
0.90) in incidence at 80–84 years and a 56% decline
(HR 0.44, 95% CI: 0.30–0.65) in centenarians between
1995–1999 and 2010–2014. Declining trends in classic
cardiovascular risk factors in recent years, including re-
ductions in smoking, high blood pressure, and cholesterol
levels [29–31], may be contributing to the observed reduc-
tions in cardiovascular and respiratory diseases in our
study. The use of anti-hypertensive medications has also
increased over the past two decades [31], consistent with
our observed declines in CHD and other reports on re-
ductions in CHD risk [32] and CHD mortality [26]. In
contrast, recent research in the UK report mortality rising
in many places among pensioners over 85, possibly linked
to increasing austerity measures [33], which may be ex-
plained by a shift in morbidity and mortality away from
CVD and towards other types of fatal chronic conditions
and impairments. Changes in COPD incidence rates over
time have not been reported in the UK elderly and reports
from the United States give conflicting results [34, 35].
Among adults in the UK, a peak in age-sex standardized
COPD incidence was reported in 2004, suggesting we may
have reached a possible summit of COPD incidence and
prevalence in England overall [36], however we report
consistent declines in COPD incidence since 1995–1999
in all age-groups of senior elderly. Diabetes prevalence has
increased worldwide [37], as has the age-adjusted inci-
dence of diabetes in the US [38] and the distribution of
obesity as a key risk factor for diabetes [39, 40]. Our
findings reveal that increases in diabetes risk extend to
all age-groups of senior elderly beyond 80 years of age.
Table 3 Age-specific changes in incidence of selected chronic conditions, 1995 to 2014
Condition Age
group
(years)
Hazard ratioa (95% CI)
1995-1999 2000-2004 2005-2009 2010-2014
CHD 80-84 Ref. 0.93 (0.88 to 0.98) 0.63 (0.59 to 0.67) 0.54 (0.50 to 0.58)
85-89 Ref. 0.88 (0.82 to 0.94) 0.62 (0.58 to 0.66) 0.55 (0.51 to 0.60)
90-94 Ref. 0.90 (0.82 to 0.99) 0.67 (0.61 to 0.74) 0.59 (0.67 to 0.76)
95-99 Ref. 0.92 (0.78 to 1.10) 0.67 (0.56 to 0.79) 0.70 (0.59 to 0.84)
100+ Ref. 0.78 (0.46 to 1.33) 0.56 (0.32 to 0.96) 1.96 (1.17 to 3.30)
Stroke 80-84 Ref. 0.95 (0.88 to 1.02) 0.80 (0.74 to 0.87) 0.83 (0.76 to 0.90)
85-89 Ref. 0.83 (0.77 to 0.89) 0.68 (0.63 to 0.73) 0.71 (0.66 to 0.77)
90-94 Ref. 0.78 (0.71 to 0.84) 0.63 (0.58 to 0.69) 0.59 (0.54 to 0.65)
95-99 Ref. 0.79 (0.69 to 0.91) 0.56 (0.48 to 0.64) 0.53 (0.46 to 0.62)
100+ Ref. 0.58 (0.40 to 0.85) 0.51 (0.35 to 0.74) 0.44 (0.30 to 0.65)
COPD 80-84 Ref. 0.66 (0.62 to 0.71) 0.63 (0.59 to 0.68) 0.59 (0.54 to 0.64)
85-89 Ref. 0.57 (0.52 to 0.62) 0.52 (0.48 to 0.56) 0.47 (0.43 to 0.52)
90-94 Ref. 0.47 (0.42 to 0.53) 0.35 (0.31 to 0.40) 0.36 (0.32 to 0.41)
95-99 Ref. 0.40 (0.32 to 0.51) 0.28 (0.22 to 0.35) 0.24 (0.18 to 0.30)
100+ Ref. 0.44 (0.23 to 0.86) 0.31 (0.16 to 0.62) 0.15 (0.07 to 0.35)
Cancer 80-84 Ref. 1.08 (1.02 to 1.15) 1.31 (1.24 to 1.39) 1.52 (1.43 to 1.61)
85-89 Ref. 1.07 (1.00 to 1.14) 1.36 (1.28 to 1.45) 1.45 (1.36 to 1.54)
90-94 Ref. 1.15 (1.05 to 1.26) 1.33 (1.22 to 1.45) 1.38 (1.26 to 1.50)
95-99 Ref. 1.08 (0.91 to 1.28) 1.20 (1.02 to 1.42) 1.44 (1.22 to 1.70)
100+ Ref. 0.87 (0.46 to 1.63) 1.17 (0.65 to 2.12) 1.69 (0.95 to 3.00)
Diabetes mellitusb 80-84 Ref. 1.62 (1.46 to 1.78) 2.02 (1.83 to 2.23) 2.18 (1.96 to 2.42)
85-89 Ref. 2.45 (2.01 to 2.99) 3.65 (3.02 to 4.41) 5.41 (4.47 to 6.53)
CI confidence interval
aAdjusted for time and sex
bNo incident diabetes events over 90 years of age
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Increasing risk of cancer in all age-groups of our cohort
is supported by reports from Cancer Research UK for
individuals aged 75 and over [41], as well as increasing
adiposity indicators and obesity [30] reported for the
UK in recent decades.
The occurrence of new age-related impairments in our
cohort, particularly degenerative mental health condi-
tions, have risen steadily since the mid-90s. The reasons
for this change remain poorly understood, but may be
resulting from increased longevity associated with lower
risk of cardiovascular mortality [35]. Age-specific de-
mentia prevalence in the UK among over-65 s was previ-
ously reported to have fallen between 1989 and 2008
[42], contrasting to our findings showing an increasing
frequency of new dementia and cognitive impairment
diagnoses in over-80s over the past two decades. These
opposing trends may be indicative of a shift in dementia
towards more extreme ages, with falling prevalence in
younger elderly and increasing incidence in the senior
elderly. Our observed increases in the risk of hearing im-
pairment may be explained by better diagnosis in pri-
mary care over time or improved access to treatment
resulting in increased recording of diagnostic codes in
CPRD. It is also possible that there have been improve-
ments in the delivery of care, which could explain the
observed declines in visual impairment among over-80s
as a result of improvements in diabetic retinopathy
screening and increased rates of cataract extractions. At
older age groups, the incidence of falls and fractures pre-
sented large increases over time, with larger increases in
fractures compared to falls. Increasing polypharmacy in
older age, with a greater likelihood of drug interactions
Fig. 3 Sex-specific incidence rates of morbidities and impairments by age. Legend: Blue, males; Red, females; Green, overall
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or inappropriate prescribing may sometimes contribute
to iatrogenic risks such as falls [31, 43, 44]. This increase
may also be attributed to increasing numbers of older
people living alone in the UK and not making appropri-
ate adaptations to their homes, as recently reported by
the International Longevity Centre (ILC-UK) [45]. Re-
cent increases in age-related impairments in our cohort
reveal an important emerging characteristic of the
current stage of epidemiologic transition.
Strengths and limitations
This study has the strengths of a large nationally repre-
sentative data resource, enabling us to analyze longitu-
dinal demographic data for up to 7% of the UK
Table 4 Age-specific changes in incidence of selected age-related impairments over the age of 80 years, 1995 to 2014
Condition Age
group
(years)
Hazard ratioa (95% CI)
1995-1999 2000-2004 2005-2009 2010-2014
Dementia 80-84 Ref. 1.28 (1.17 to 1.39) 1.85 (1.70 to 2.01) 2.94 (2.70 to 3.21)
85-89 Ref. 1.21 (1.12 to 1.30) 1.55 (1.44 to 1.66) 2.40 (2.23 to 2.57)
90-94 Ref. 1.16 (1.06 to 1.26) 1.50 (1.37 to 1.63) 2.03 (1.87 to 2.20)
95-99 Ref. 1.32 (1.12 to 1.55) 1.76 (1.51 to 2.04) 2.43 (2.09 to 2.82)
100+ Ref. 1.30 (0.70 to 2.42) 2.18 (1.21 to 3.90) 2.52 (1.41 to 4.50)
Cognitive/memory 80-84 Ref. 2.29 (2.05 to 2.55) 3.61 (3.25 to 4.01) 5.57 (5.01 to 6.20)
85-89 Ref. 2.36 (2.11 to 2.63) 3.84 (3.46 to 4.27) 5.64 (5.08 to 6.27)
90-94 Ref. 2.53 (2.16 to 2.98) 4.25 (3.64 to 4.96) 6.30 (5.40 to 7.34)
95-99 Ref. 2.49 (1.81 to 3.42) 4.31 (3.17 to 5.84) 6.62 (4.89 to 8.95)
100+ Ref. 2.28 (0.67 to 7.77) 3.96 (1.22 to 12.8) 6.02 (1.88 to 19.3)
MSK pain 80-84 Ref. 1.06 (1.02 to 1.10) 1.30 (1.25 to 1.35) 1.26 (1.21 to 1.32)
85-89 Ref. 1.06 (1.01 to 1.11) 1.29 (1.23 to 1.35) 1.22 (1.16 to 1.28)
90-94 Ref. 1.00 (0.93 to 1.06) 1.25 (1.17 to 1.33) 1.18 (1.11 to 1.26)
95-99 Ref. 1.00 (0.88 to 1.14) 1.33 (1.18 to 1.50) 1.32 (1.16 to 1.49)
100+ Ref. 0.83 (0.55 to 1.25) 1.45 (1.00 to 2.10) 1.63 (1.12 to 2.37)
Falls 80-84 Ref. 1.08 (1.03 to 1.13) 1.18 (1.13 to 1.24) 1.26 (1.19 to 1.32)
85-89 Ref. 1.05 (1.00 to 1.10) 1.11 (1.06 to 1.16) 1.18 (1.13 to 1.23)
90-94 Ref. 0.96 (0.91 to 1.02) 1.11 (1.05 to 1.17) 1.13 (1.07 to 1.19)
95-99 Ref. 1.03 (0.94 to 1.14) 1.21 (1.11 to 1.33) 1.25 (1.14 to 1.37)
100+ Ref. 1.10 (0.81 to 1.49) 1.33 (0.99 to 1.79) 1.50 (1.12 to 2.02)
Fractures 80-84 Ref. 0.94 (0.89 to 1.00) 1.18 (1.12 to 1.26) 1.38 (1.30 to 1.47)
85-89 Ref. 0.96 (0.91 to 1.02) 1.20 (1.13 to 1.27) 1.49 (1.41 to 1.58)
90-94 Ref. 0.97 (0.90 to 1.05) 1.19 (1.11 to 1.28) 1.42 (1.32 to 1.53)
95-99 Ref. 1.11 (0.97 to 1.27) 1.41 (1.24 to 1.60) 1.61 (1.42 to 1.83)
100+ Ref. 0.95 (0.64 to 1.41) 1.32 (0.91 to 1.92) 1.57 (1.09 to 2.27)
Hearing impairment 80-84 Ref. 1.14 (1.08 to 1.19) 1.26 (1.20 to 1.32) 1.28 (1.22 to 1.35)
85-89 Ref. 1.21 (1.15 to 1.28) 1.34 (1.27 to 1.41) 1.32 (1.25 to 1.39)
90-94 Ref. 1.22 (1.13 to 1.32) 1.40 (1.30 to 1.51) 1.43 (1.32 to 1.54)
95-99 Ref. 1.40 (1.20 to 1.62) 1.65 (1.43 to 1.91) 1.81 (1.56 to 2.10)
100+ Ref. 0.85 (0.51 to 1.41) 1.41 (0.88 to 2.25) 1.75 (1.10 to 2.78)
Visual impairment 80-84 Ref. 0.77 (0.72 to 0.82) 0.62 (0.58 to 0.66) 0.50 (0.46 to 0.54)
85-89 Ref. 0.85 (0.80 to 0.91) 0.69 (0.65 to 0.74) 0.54 (0.50 to 0.59)
90-94 Ref. 0.92 (0.84 to 1.01) 0.86 (0.79 to 0.95) 0.67 (0.61 to 0.74)
95-99 Ref. 1.03 (0.85 to 1.25) 1.00 (0.83 to 1.20) 0.88 (0.73 to 1.07)
100+ Ref. 0.76 (0.44 to 1.31) 0.74 (0.44 to 1.25) 0.51 (0.29 to 0.90)
CI confidence interval
aAdjusted for time and sex
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population. Use of primary care EHRs facilitated analysis
of longitudinal and age-specific estimates for a wide range
of chronic morbidities and age-related impairments in a
large sample. Approximately 98% of the UK population
will be registered with primary care [46], ensuring our re-
sults are population-based. We acknowledge that mis-
classification of birth year may occur, especially for people
born longer ago, due to poor recording practices at time
of birth or if birth date is reported by proxies. The analysis
used clinical records for health conditions and these may
be affected by misclassification including over- or under-
recording, or changes in the depth and quality of coding,
which may vary over time. In general, diagnoses recorded
into EHRs have high predictive value [47], but we acknow-
ledge that diagnoses may be less reliable at older ages if,
for example, fewer investigations are performed. Record-
ing of age-related conditions such as dementia may be
underestimated, however our data should provide reliable
figures for relative changes over time. There may also be
changes over recent years in the use of particular diag-
nostic labels. While these reservations suggest the need
for further epidemiological studies in very old people,
prospective cohort studies may suffer from different
limitations including biases from differential selection,
participation, and attrition. These may be minimized
through the use of EHRs for cohort selection and
follow-up.
Conclusions
Empirical evidence reveals that the “fourth stage” of epide-
miologic transition is more nuanced than originally pro-
posed. At the oldest ages, populations exhibit important
epidemiologic changes that are not yet well-characterized
beyond 80 years. We recommend that, where data permits,
the practice of reporting on “the elderly” as one group
must change in order to more fully understand the distri-
bution of disease and disability in different subgroups of
the over-80 population. This will be a vital component in
producing better evidence to improve the health and care
of the senior elderly, and to help inform a shift in thinking
from “chronic disease prevention” to “healthy aging” that is
important at the oldest ages. Greater acknowledgement
among policymakers and clinicians of the observed growth
in multi-morbidity and shift away from the presently exist-
ing single-disease framework in health care [48] will be
crucial in the coming years to better manage the health
care needs of an aging population. Improved public health
interventions are also required to reduce levels of obesity
in the middle-aged and elderly populations in order to fa-
cilitate the prevention of new diabetes and cancer diagno-
ses in older age. However, more evidence is also needed to
inform the prevention of accumulating functional deficits
and age-related impairments.
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